Latest Headlines
-
NIST’s Heart-On-A-Chip: A Microfluidic Marvel Shaping The Future Of Cardiovascular Research
2/6/2024
In a major step forward in drug development, researchers at the National Institute of Standards and Technology (NIST) have developed a tool for building a system known as heart-on-a-chip (HoC).
-
Nascent Biotech And Manhattan BioSolutions Collaborate To Explore Pritumumab Antibody-Drug Conjugates
2/6/2024
Nascent Biotech, Inc. ("Nascent Biotech", "Nascent"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies for the treatment of various cancers and viral infections, announced today it has entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (Manhattan Bio), an emerging biotech company focused on precision biologics, to explore antibody-drug conjugates (ADCs) using Nascent's lead clinical candidate pritumumab (PTB) as the tumor-targeting antibody element.
-
Encoded Therapeutics Announces US IND Clearance And Australian CTA Approval For Dravet Syndrome Gene Therapy Candidate ETX101
2/6/2024
Encoded Therapeutics Inc., a biotechnology company focused on developing genetic medicines for severe central nervous system (CNS) disorders, today outlined the global development strategy for its lead gene therapy candidate, ETX101, for the treatment of SCN1A+ Dravet syndrome. Individuals with Dravet syndrome, the most common developmental and epileptic encephalopathy, experience a spectrum of clinical symptoms, including treatment-resistant seizures and neurodevelopmental stagnation.
-
Biofrontera Inc. Announces FDA Filing Of Supplemental New Drug Application For Ameluz To Permit Up To Three Tubes Per Use
2/5/2024
Biofrontera Inc. ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that the U.S. Food and Drug Administration (FDA) has issued a "no filing review issues identified" letter regarding the sNDA (supplementary New Drug Application) submitted by its licensor Biofrontera Bioscience GmbH to increase the maximally approved dosage from one to three tubes of Ameluz per treatment.
-
MGI Enters Strategic Partnership With Prepaire Labs To Advance Drug Discovery And Precision Medicine
2/5/2024
MGI, a company committed to building core tools and technology to lead life science, today announced its collaboration with Prepaire Labs at MEDLAB Middle East 2024 to further empower precision medicine.
-
Novo Holdings To Acquire CDMO Catalent Pharma Solutions For $16.5 Billion
2/5/2024
Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, today announced that they have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis.
-
Bruker Introduces The Ingenious Novel ‘Triceratops’ SPR #64 Surface Plasmon Resonance System For Drug Discovery At SLAS2024
2/5/2024
At the SLAS2024 International Conference and Exhibition, Bruker Corporation today introduced the ground-breaking, new ‘Triceratops’ SPR #64 Surface Plasmon Resonance (SPR) instrument.
-
BridgeBio Pharma Announces U.S. Food And Drug Administration (FDA) Acceptance Of New Drug Application (NDA) For Acoramidis For The Treatment Of Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
2/5/2024
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for acoramidis, an investigational drug for the treatment of ATTR-CM.
-
SCIEX Expands High-Throughput Screening Solutions With Echo MS+ System
2/2/2024
SCIEX, a global leader in life science analytical technologies, launches the Echo MS+ system at SLAS 2024.
-
Yokogawa Introduces CellVoyager High-Content Analysis System CQ3000
1/31/2024
Yokogawa Electric Corporation announces the development of the CellVoyager High-Content Analysis System CQ3000 as part of the CellVoyager high-content analysis (HCA) system solution lineup, which includes cell observation devices and image analysis software.